Testosterone Replacement Therapy in Smokers: Guidelines and Recommendations
Smoking status does not represent an absolute contraindication to testosterone replacement therapy (TRT), but smokers require more intensive monitoring, particularly for cardiovascular and hematologic complications, and should be strongly counseled on smoking cessation before and during treatment.
Key Principle: Smoking Cessation is Priority
The most important intervention for smokers considering TRT is cessation of tobacco abuse 1. This should be addressed before initiating therapy, as smoking cessation can serve as a motivational tool when discussing anticipated improvements in sexual function and overall health outcomes.
Critical Evidence on Smoking and TRT Outcomes
Smokers experience diminished cardiovascular benefits from TRT compared to nonsmokers. A 2017 study of 18,055 men demonstrated that while testosterone normalization reduced all-cause mortality in both groups, smokers did not experience the protective effect against myocardial infarction that nonsmokers received (HR 1.096 in smokers vs HR 0.717 in nonsmokers, P<0.001) 2. Even more concerning, current smokers with normalized testosterone had significantly higher rates of MI (HR 1.706), stroke (HR 1.590), and all-cause mortality (HR 1.242) compared to nonsmokers with normalized testosterone 2.
Standard Diagnostic and Treatment Approach
Before Initiating TRT in Smokers:
Baseline evaluation must include:
- Two morning fasting serum total testosterone measurements showing levels <300 ng/dL 3
- Hematocrit measurement (baseline >50% is a relative contraindication) 3
- Digital rectal examination and PSA (for men ≥40 years with PSA >0.6 ng/ml) 3
- Assessment for sleep apnea and hypoxia risk 3
- Evaluation of cardiovascular risk factors and optimization of hypertension, hyperlipidemia, and diabetes control 1
Special Considerations for Smokers:
Hematocrit monitoring is particularly critical because:
- Testosterone increases hemoglobin dose-dependently 3
- Smokers may have baseline polycythemia from chronic hypoxia
- If hematocrit exceeds 54%, stop therapy immediately, evaluate for hypoxia and sleep apnea, and reinitiate only with reduced dosing 3
Monitoring Protocol for Smokers on TRT
Follow this intensified schedule:
Initial Phase (First Year):
- 3-6 months: Assess symptom response, measure testosterone (target mid-normal range 450-600 ng/dL), check hematocrit, PSA, and digital rectal examination 3
- 12 months: Repeat all assessments; discontinue if no improvement in target symptoms 4
Ongoing Monitoring (Annual):
- Testosterone levels
- Hematocrit (critical in smokers due to combined risk)
- PSA and digital rectal examination (age-appropriate)
- Cardiovascular symptom assessment
- Sleep apnea screening 3
Red Flags Requiring Urological Consultation:
- PSA increase >1.4 ng/ml within 12 months 3
- PSA velocity >0.4 ng/ml/year (after 6 months baseline) 3
- Abnormal digital rectal examination 3
Formulation Selection
Intramuscular testosterone (enanthate or cypionate) should be preferred over transdermal formulations in smokers due to:
- Significantly lower cost with similar efficacy 4
- More predictable dosing in patients with compliance concerns
- Easier monitoring with mid-injection interval testosterone measurements 3
Dosing: 50-150 mg intramuscularly every 7-14 days, or 100 mg on days 1,11, and 21 of each month 1
Absolute and Relative Contraindications
Do not initiate TRT in smokers with:
- Untreated prostate or breast cancer 5
- Severe heart failure 5
- Recent MI or stroke (within 4 months) 6
- Hematocrit >50% until evaluated and optimized 3
Clinical Decision Algorithm
- Confirm hypogonadism: Two morning testosterone <300 ng/dL + symptoms
- Mandate smoking cessation counseling before proceeding
- Complete baseline evaluation with emphasis on hematocrit, cardiovascular risk, and sleep apnea
- If baseline hematocrit >50%: Defer TRT until evaluated for hypoxia/sleep apnea
- Initiate intramuscular testosterone at conservative doses
- Monitor at 3-6 months: If hematocrit >54%, stop immediately
- Reassess at 12 months: Discontinue if no symptomatic benefit
- Continue only if: Patient quits smoking or demonstrates clear benefit outweighing cardiovascular risks
Critical Pitfall
The most important caveat: Active smoking may completely negate the cardiovascular protective effects of testosterone normalization 2. Clinicians must explicitly discuss this with patients—TRT in active smokers provides mortality benefit but not MI protection, making smoking cessation non-negotiable for optimal outcomes. The risk-benefit discussion should emphasize that continuing to smoke while on TRT maintains elevated cardiovascular risk despite testosterone normalization.